MorphoSys proposes $150M NASDAQ listing

MorphoSys AG (Xetra:MOR; Pink:MPSYY) proposed Thursday to raise up to $150 million and list its ADSs on NASDAQ in a follow-on underwritten by Goldman Sachs, J.P. Morgan, Leerink, Berenberg and JMP.

The company is planning to submit a rolling BLA to FDA in 2H19 for MOR208, an FC-optimized human mAb against CD19, to treat relapsed or refractory diffuse large B cell lymphoma (DLBCL) (see BioCentury Extra, March 13)...